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Abstract
Introduction The persistence of circulating tumor cells (CTC) in
breast cancer patients might be associated with stem cell like
tumor cells which have been suggested to be the active source
of metastatic spread in primary tumors. Furthermore, these cells
also may undergo phenotypic changes, known as epithelial-
mesenchymal transition (EMT), which allows them to travel to
the site of metastasis formation without getting affected by
conventional treatment. Here we evaluated 226 blood samples
of 39 metastatic breast cancer patients during a follow-up of
palliative chemo-, antibody – or hormonal therapy for the
expression of the stem cell marker ALDH1 and markers for EMT
and correlated these findings with the presence of CTC and
response to therapy.
Methods 2 × 5 ml blood was analyzed for CTC with the
AdnaTest BreastCancer (AdnaGen AG) for the detection of
EpCAM, MUC-1 and HER2 transcripts. The recovered c-DNA
was additionally multiplex tested for three EMT markers [Twist1,
Akt2, PI3Kα] and separately for the tumor stem-cell markers
ALDH1. The identification of EMT markers was considered
positive if at least one marker was detected in the sample.
Results 97% of 30 healthy donor samples investigated were
negative for EMT and 95% for ALDH1 transcripts. CTC were
detected in 69/226 (31%) cancer samples. In the CTC (+)
group, 62% were positive for at least one of the EMT markers
and 69% for ALDH1, respectively. In the CTC (-) group the
percentages were 7% and 14%, respectively. In non-
responders, EMT and ALDH1 expression was found in 62% and
44% of patients, in responders the rates were 10% and 5%,
respectively.
Conclusions Our data indicate that a major proportion of CTC
of metastatic breast cancer patients shows EMT and tumor stem
cell characteristics. Further studies are needed to prove
whether these markers might serve as an indicator for therapy
resistant tumor cell populations and, therefore, an inferior
prognosis.
Introduction
Recurrence in breast cancer is explained by hematogenous
dissemination of tumor cells in very early stages of the disease
not being detectable by common staging procedures [1,2].
Although the prognostic value of these cells has been shown
by several groups [3-7], it is assumed that the metastatic
potential of a tumor is based on the presence of a low number
of stem cell-like tumor cells that have been identified in tumor
tissue to be the active source of metastatic spread [8-10]. In
this regard, one study confirmed a putative stem cell pheno-
type in disseminated tumor cells (DTCs) [11], and another
study showed that the majority of early DTCs detected in the
bone marrow of breast cancer patients with a CD44+/CD24-
phenotype correlated with a higher prevalence of bone metas-
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tases [12]. One candidate marker for a cancer stem cell phe-
notype is aldehyde dehydrogenase 1 (ALDH1), a detoxifying
enzyme responsible for the oxidation of intracellular aldehydes
[13].
However, development of metastases depends on multiple
factors that determine overall tumor cell growth, survival, ang-
iogenesis, and invasion. For epithelial malignancies, the epi-
thelial-mesenchymal transition (EMT) is considered to be the
crucial event in the metastatic process, which involves the dis-
ruption of epithelial cell homeostasis and the acquisition of a
migratory mesenchymal phenotype allowing these cells to
travel to the site of metastasis formation without being affected
by conventional treatment [14,15]. The EMT appears to be
controlled by signal-transduction pathways such as the Wnt
and transforming growth factor β pathways, both of which can
be aberrantly activated during neoplasia. One candidate is the
TWIST gene, described to bind to E-box elements on the Akt2
promoter and to enhance its transcriptional activity and, thus,
is likely to be related to the EMT phenomenon in cancer cells
[16-18]. Also involved is PI3Kα, which activates the Akt1 and
Akt2 Ser/Thr kinase, responsible for proliferation and antiap-
optotic function [19-22].
Assuming that metastasis requires a dissemination of tumor
stem cells or tumor cells showing EMT, it seems likely that
such cells should be detectable among the CTCs found in the
circulation of breast cancer patients.
In this study, we evaluated 226 blood samples of 39 meta-
static breast cancer patients during a follow-up of palliative
chemo-, antibody, or hormonal therapy for the expression of
ALDH1 and the EMT markers TWIST, Akt2, and PI3Kα, and
correlated these findings with the presence of CTCs and the
response to therapy.
Materials and methods
Patient population
The study was conducted at the Department of Obstetrics and
Gynecology in collaboration with the Department of Internal
Medicine (Cancer Research) at the University Hospital in
Essen. In total, 226 blood samples of 39 patients have been
studied since October 2007.
Eligibility criteria
The eligibility patient criteria were as follows: age, 18 years or
older; measurable or evaluable metastatic breast cancer; pre-
dicted life expectancy, 2 months or more; Eastern Cooperative
Oncology Group (ECOG) scores for performance status of 0
to 2; no severe uncontrolled comorbidities or medical condi-
tions; and no second malignancies.
Patients either had a relapse of breast cancer diagnosed years
before and were to start chemotherapy or had a documented
progressive breast cancer before receiving a new endocrine,
chemo-, or experimental therapy. Prior adjuvant treatment,
radiation, or any other treatment of metastatic disease was
permitted. Exclusion criteria were other malignancies except
breast cancer. All specimens were obtained after written
informed consent and collected by using protocols approved
by the institutional review board (05/2856).
Response criteria
Before starting a new treatment, patients underwent an evalu-
ation of metastatic sites with ultrasound, radiographs, or com-
puted tomography. Blood samples were collected for
laboratory evaluations, including assaying CEA and Ca 15-3
plasma levels, as well as the isolation and characterization of
CTCs. Reevaluations of disease status were done by the same
techniques every 8 to 12 weeks, depending on the treatment
schedule, until the loss or death of a patient.
Response to therapy was evaluated according to the
Response Evaluation Criteria in Solid Tumors (RECIST):
complete response (CR), disappearance of all target lesions;
partial response (PR), at least 30% decrease in the sum of the
LD (longest diameter) of target lesions, taking as reference the
baseline sum LD; progressive disease (PD), at least 20%
increase in the sum of the LD target lesions, taking as refer-
ence the smallest sum LD recorded since the treatment
started or the appearance of one or more new lesions; stable
disease (SD), neither sufficient shrinkage to qualify for PR nor
sufficient increase to qualify for PD, taking as reference the
smallest sum LD since the treatment started.
Immunohistochemical analysis
For each of the 39 patients, the tumor type, TNM staging, and
grading were assessed according to the WHO classification
of tumors of the breast [23] and the sixth edition of the TNM
Classification System [24] when the patients were first seen
with the primary tumor. The estrogen (ER) and the progester-
one (PR) receptor status were determined with immunohisto-
chemistry. The DAKO score for the expression of HER2 was
reevaluated with the HercepTest® (Dako). FISH analysis in
cases of 2+ staining, as determined with the HercepTest®,
was performed as described elsewhere [25].
IGROV cell line
The ovarian cancer cell line was purchased from the ATCC
(American Tissue Culture Collection, Rockville, MD) and cul-
tured in a humidified incubator at 37°C in an atmosphere of
5% CO2 and 95% air. The cell line was maintained in RPMI
medium supplemented with 10% heat-inactivated fetal bovine
serum and 1% penicillin/streptavidin (Biochrom KG, Ser-
omed, Berlin, Germany).
Sampling of biologic material
Double samples of 5 ml EDTA blood were collected for isola-
tion of CTCs before the application of therapeutic substances
with an S-Monovette® (Sarstedt AG & Co, Nümbrecht, Ger-Available online http://breast-cancer-research.com/content/11/4/R46
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many) and stored at 4°C until further examination. The samples
were processed immediately or not later than 4 hours after
blood withdrawal. Double sampling of patient specimens was
performed to avoid technical dropouts. However, the overall
correspondence in two patient samples was more than 90%.
Healthy controls
Blood (5 ml) was collected from 30 healthy donors aged 23 to
73 years for the determination of specificity and sensitivity of
the applied tests for the determination of ALDH1 and EMT
markers.
Tumor cell enrichment/selection
The 226 blood samples were taken from 39 patients with met-
astatic breast cancer. The AdnaTest BreastCancerSelect
(AdnaGen AG, Langenhagen, Germany) facilitates the immu-
nomagnetic enrichment of tumor cells via epithelial and tumor-
associated antigens. Two antibodies against the epithelial
antigen MUC1 and one antibody against the epithelial glyco-
protein GA733-2 (EpCAM) are conjugated to magnetic beads
(Dynabeads) for the labelling of tumor cells in peripheral blood.
In brief, the blood samples were incubated with a ready-to-use
antibody mixture commercialized as AdnaTest BreastCan-
cerSelect, according to the manufacturer's instructions. The
labelled cells were extracted by a magnetic particle concentra-
tor (MPC). Subsequently, mRNA isolation from lysed, enriched
cells was performed according to the manufacturer's instruc-
tions with the Dynabeads mRNA DIRECT™ Micro Kit (Invitro-
gen, Karlsruhe, Germany), included in the AdnaTest
BreastCancerDetect. Reverse transcription resulted in cDNA,
which was the template for tumor cell detection and character-
ization by multiplex RT-PCR. Sensiscript®  Reverse Tran-
scriptase (QIAGEN GmbH, Hilden, Germany) was used for
the reverse transcription because of its high sensitivity (recom-
mended for amounts of less than 50 ng RNA) in combination
with oligo(dT)-coupled Dynabeads of the mRNA DIRECT™
Micro Kit, according to the manufacturer's instructions. cDNA
was synthesized in a thermocycler under the following condi-
tions: Reverse transcription was performed at 37°C for 60
minutes followed by 3 minutes at 93°C for inactivation of the
reaction. The resulting cDNA was stored at -20°C until further
use.
Tumor cell detection
The Adnatest BreastCancerDetect was used for the detection
of breast cancer-associated gene expression in immunomag-
netically enriched tumor cells by reverse transcription and
PCR. The analysis of tumor-associated mRNA isolated from
CTC tumor cells was performed in a multiplex PCR for three
tumor-associated transcripts: HER2, MUC1, and GA733-2.
The thermal profile used for multiplex RT-PCR was as follows:
After a 15-minute denaturation at 95°C, 35 PCR cycles were
carried out by denaturation at 94°C for 1 minute, annealing/
extension at 60°C for 1 minute, and elongation for 1 minute at
72°C. Subsequently, termination of the reaction was carried
out at 72°C for 10 minutes, followed by storage of the samples
at 4°C.
The primers generate fragments of the following sizes:
GA733-2, 395 base pairs (bp); MUC1, 293 bp; and HER2,
actin, 114 bp.
The AdnaTest TumorStemCell/The AdnaTest EMT
Both tests require the enrichment of CTCs from 5 ml blood by
using the AdnaTest BreastCancerSelect before the singleplex
PCR assay to analyze ALDH1, the multiplex PCR assay to ana-
lyze EMT markers, and actin as an internal control. Contami-
nating leukocytes (about 1,500 per sample) are reduced 10-
fold by using a special washing procedure (AdnaWash buffer).
This allows the proper differentiation of EMT and tumor stem
cell-expression profiles with a specificity of more than 90%,
which was confirmed in healthy donor samples.
The thermal profile used for EMT multiplex RT-PCR was as fol-
lows. After a 15-min denaturation at 95°C, 35 PCR cycles
were carried out by denaturation at 94°C for 30 seconds,
annealing/extension at 60°C for 30 seconds, and elongation
for 45 seconds at 72°C. Subsequently, termination of the
reaction was carried out at 72°C for 10 minutes, followed by
storage of the samples at 4°C. The primers generate frag-
ments of the following sizes: Akt-2, 306 bp; TWIST 1, 203 bp;
PI3Kα, 595 bp; and Actin, 119 bp.
The thermal profile used for ALDH1 singleplex PCR was as fol-
lows. After a 15-minute denaturation at 95°C, 35 PCR cycles
were carried out by denaturation at 94°C for 30 seconds,
annealing/extension at 51°C for 30 seconds, and elongation
for 30 seconds at 72°C. Subsequently, termination of the
reaction was carried out at 72°C for 5 minutes followed by
storage of the samples at 4°C. The generated fragment size
for ALDH1 is 165 bp.
Evaluation of data
Visualization of all PCR fragments was carried out with a 2100
Bioanalyzer by using the DNA 1000 LabChips (Agilent Tech-
nologies) and the Expert Software Package (version
B.02.03.SI307). The test is considered positive if a PCR frag-
ment of at least one tumor-associated transcript is clearly
detected. With the software package for evaluation of the data
on the Agilent 2100 Bioanalyzer, peaks with a concentration
of > 0.15 ng/μl are positive for the transcripts GA733-2,
MUC1, and HER2. Peaks that are not detected at this setting
are negative (concentration of less than 0.15 ng/μl). The cut-
off values for the EMT markers and ALDH1 are 0.2 ng/μl for
Akt2, 0.15 ng/μl for TWIST1, 0.25 ng/μl for PI3Kα, and 0.15
ng/μl for ALDH1.Breast Cancer Research    Vol 11 No 4    Aktas et al.
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Results
Establishment of a blood test for detection of stem cell 
and EMT markers
The ovarian carcinoma cell line IGROV1 was used because all
markers studied were expressed by that cell line. The analytic
sensitivity was determined by the detection of a low number of
target cells (5 IGROV cells spiked into 5 ml blood of healthy
donors) by using the AdnaTest BreastCancer procedure. The
spiking experiments revealed 80% recovery of the IGROV
cells (data not shown). Applying an amplicon cut-off value of
0.2 ng/μl for Akt2, 0.15 ng/μl for TWIST, 0.25 ng/μl for PI3Kα,
and 0.15 ng/μl for ALDH1, 97% of 30 healthy donor samples
investigated were negative for EMT, and 95%, for ALDH1 tran-
scripts.
Patients' characteristics
Inclusion criteria
All patients studied had metastatic breast cancer. Patients
either had a relapse of breast cancer diagnosed years before
and were to start chemotherapy or had a documented pro-
gressive breast cancer before receiving a new endocrine,
chemo-, or experimental therapy.
Table 1 describes the patients' characteristics before onset of
the study. The table is divided into three different parts: patient
characteristics at the time of first diagnosis, sites of metastasis
when metastasis was diagnosed, and "treatment," is divided
into Treatment at primary diagnosis and Treatment in the met-
astatic setting.
In total, 39 patients were enrolled since October 2007. As
shown in Table 1, the patients ranged in age from 35 to 78
years. Only 10 patients had primary metastatic breast cancer.
Most patients had ductal breast cancer. Moderately and poorly
differentiated tumors were predominant. Most patients had
visceral and nonvisceral metastasis, and 31 and 26 primary
tumors were ER and PR positive, respectively; 11 primary
tumors had an overexpression of HER2 (DAKO, score 3+). The
chemotherapeutic adjuvant treatment mostly contained
anthracyclines and taxanes. Patients with metastatic tumors of
the breast received different chemotherapeutic treatments
including anthracylines, taxane, vinorelbine, and 5-FU. Most
patients were extensively pretreated before starting the collec-
tion of the blood samples. Nineteen patients received anthra-
cycline- or taxane-based chemotherapy in an adjuvant or
metastatic setting before study start. Nearly all patients with
HER2 3+ tumors received trastuzumab in the metastatic set-
ting, and only one, in the adjuvant setting.
CTC determination was performed before individual chemo-
therapy or hormonal treatment, depending on the pretreat-
ment.
Stratifying of results
In total, 39 patients were monitored for CTCs during chemo-
therapy over a median period of 9 months (2 to 18 months)
and stratified into responders and nonresponders. Patients
(16 of 39) were monitored for between 9 and 18 months. Dur-
ing that period of monitoring, they were both responders and
nonresponders. Thus, these patients appear twice in the cal-
culation of results, resulting in 21 responders and 34 nonre-
sponders for all further evaluations.
Correlation of CTC and response
In total, CTCs were detected in 69 (31%) of all 226 cancer
samples investigated during follow-up of the disease. In the
CTC-positive samples investigated, at least two markers were
overexpressed in the majority of the cases (60%), whereas
overexpression of only one of the markers was observed in
24% of the cases for MUC1, in 13% for HER2, and 3% for
Ga733-2 (data not shown). When these results were corre-
lated with response to therapy, 24 (71%) of 34 nonrespond-
ers and 2 (10%) of 21 responders were found in the CTC+
group, whereas 10 (29%) of 34 nonresponders and 19 (90%)
of 21 responders were found in the CTC- group (Figure 1).
Expression of CD34
Twelve patients initially positive for CTCs and positive for at
least one of the EMT markers or ALDH1 or both were further
tested for CD34 to exclude potential interference of normal
hematopoietic stem cells in the blood samples. However, none
of the samples was positive for CD34 (data not shown).
Correlation of CTC and EMT markers/ALDH1
All samples were further examined for ALDH1 and EMT mark-
ers and correlated with the presence of CTC (Figure 2a). In
the CTC+ group, 21 (81%) of 26 patients were positive for at
least one of the EMT markers or ALDH1 or both. In the CTC-
group, the percentage was 11% (3 of 29) patients, respec-
tively. Figure 2b shows a more-detailed analysis of the distri-
bution of the individual markers among the CTC+ and CTC-
groups.
In the CTC (+) group, the expression rates for the EMT markers
were 42% (TWIST), 62% (Akt2), 58% (PI3Kα), and 69% for
ALDH1. In the CTC- group, the percentages were 7%, 4%,
4%, and 14%, respectively.
Correlation of EMT markers/ALDH1 and response to 
therapy
The expression of EMT or stem cell markers or both in CTCs
was compared with the clinical follow-up results (Figure 3a).
EMT markers or ALDH1 or both were found in 25 (74%) of 34
nonresponders and in 2 (10%) of 21 responders. In contrast,
no EMT markers or ALDH1 or both were detected in 9 (26%)
of 34 nonresponders and in 19 (90%) of 21 responders. Fig-
ure 3b shows a more-detailed analysis of the distribution of the
individual markers among the responders and nonresponders.Available online http://breast-cancer-research.com/content/11/4/R46
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Table 1
Patient characteristics before study start
Patient characteristics at first diagnosis Number
Number of patients 39
Median age (years) 46 (range, 35–78)
Staging of the primary tumor is 1
I5
II 21
III 6
IV 6
Histology Ductal 24
Lobular 5
Ductal/lobular 2
Other* 5
Not known 3
Grading 1 4
21 6
31 8
Not known 1
Receptor expression
Estrogen and progesterone receptor Pos 26
Estrogen receptor Pos 31
Progesterone receptor Pos 26
HER2 overexpression Pos (3+)1 1
DAKO 2+/FISH- 3
Sites of metastasis
Visceral + nonvisceral 21
Visceral 11
Nonvisceral 7
Cerebral 0
Elevated markers CEA 25
Ca15-3 27
Not known 1
TreatmentBreast Cancer Research    Vol 11 No 4    Aktas et al.
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In the nonresponder group, the expression rate for the EMT
markers were 32% (TWIST), 44% (Akt2), 41% (PI3Kα), and
62% for ALDH1. In the responder group, the percentages
were 10% for each EMT marker and 5% for ALDH1.
Discussion
Recent key findings in primary tumor tissue suggest that the
metastatic potential of a tumor is based on the presence of a
low number of stem cell-like tumor cells that have been identi-
fied in tumor tissue to be the active source of metastatic
spread. Furthermore, it was shown that tumor cells that are
spreading into the circulation may undergo phenotypic
changes, known as EMT, which allows them to travel to the
site of metastasis formation without being affected by conven-
tional treatment.
Here we demonstrated that at least one or more of the EMT
markers TWIST, Akt2, and PI3Kα, as well as the stem cell
marker ALDH1 were detectable, mainly in patient samples that
also were positive for CTCs. These findings correlated with
response to breast cancer-related therapies and indicate that
a major proportion of CTCs found in the blood of cancer
patients shows EMT and tumor stem cell characteristics, and
that CTCs expressing EMT and tumor stem cell markers are an
indication for therapy-resistant cell populations and thus for an
inferior prognosis.
The potential existence of a stem cell-like cell in breast cancer
was shown by Al-Hajj and colleagues [26], who identified a
putative breast tumor stem cell-like population that is defined
by the presence of CD44 and absence of CD24. One can
assume that such tumor stem cells are disseminated from the
primary tumor into the circulation and escape therapy because
of their stem cell properties until they reach their homing
organ, where they act as seed for metastasis formation [1].
This assumption is supported by the observation that primary
tumor stem cells show an expression profile associated with
metastatic relapse in breast cancer patients [27]. More
recently, ALDH1 was found to be a specific marker for breast
cancer stem cells [28]. In our samples, ALDH1 overexpression
was found in approximately 70% of the blood samples also
positive for CTCs.
Certain evidence suggests that CTCs might be identified
partly as cancer stem cells because of similarities such as
increased resistance to chemotherapy and decreased prolifer-
ation during circulation. Similar findings were reported for
(Neo-)adjuvant treatment at primary diagnosis
Chemotherapy 19
Radiation 11
Hormone 18
Trastuzumab 1
Not known 0
Treatment in the metastatic setting
Chemotherapy line First 13
Second 4
Third 6
Fourth and more 12
Not known 0
Trastuzumab 11
Hormone therapy 23
*Medular, trabecular, secretory, neuroendocrine, adenocarcinoma.
Table 1 (Continued)
Patient characteristics before study start
Figure 1
Correlation of circulating tumor cells (CTCs) and response to therapy Correlation of circulating tumor cells (CTCs) and response to therapy. 
Patients are stratified into responders and nonresponders.Available online http://breast-cancer-research.com/content/11/4/R46
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DTCs in bone marrow, where tumor cells with a stem cell-like
phenotype were demonstrated [11]. Corresponding experi-
mental results for CTCs are still outstanding. Preliminary data,
presented at the annual meeting of the American Association
for Cancer Research 2008, identified a breast cancer stem
cell-like phenotype in blood samples of patients with breast
cancer [29]. We recently demonstrated that the presence or
disappearance of CTCs during the time course of individual
treatment is a predictor of therapy response in metastatic
breast cancer [30]. In a follow-up of these patients, we now
demonstrate that the expression of the stem cell marker
ALDH1 among CTCs is associated with therapy failure.
Assuming that breast cancer cells are very heterogeneic, the
fraction of CTCs, theoretically, should include the fraction of
tumor cells able to form metastasis.
Because the morphology of the cells cannot be shown with
this method, we cannot exclude false-positive results in some
cases. One of the molecular markers, such as MUC1 or HER2,
might be overexpressed in activated leukocytes present only in
cancer patient blood. However, in the major proportion of the
CTC-positive samples investigated in this study, at least two
markers were overexpressed in the majority of the cases
(60%), whereas overexpression of only one of the markers was
observed in 24% of the cases for MUC1, in 13% for HER2,
and in 3% for Ga733-2. Furthermore, even if false-positive
results cannot be absolutely avoided, the correlation of CTCs
detected by using the AdnaTestBreastCancer as well as the
EMT or stem cell-related mRNA profiles fits positively with
therapy response and overall survival rate. Visualization of the
cells finally will show whether the expression patterns can be
confirmed to be related to CTCs only.
The two breast cancer subtypes with bad outcome are basal-
like and HER2-like breast tumors. Clinically, basal-like breast
cancer is characterized as the triple-negative phenotype (ER,
PR, HER2, all negative) and as resembling stem-like cells,
composed mainly of cells expressing the cancer stem cell
markers CD44+ and cytokeratin 5/6 [31-33]. In our patient
group analyzed, only 1 of 39 patients was characterized as tri-
ple-negative at first diagnosis. In contrast, 11 of our patients
were initially classified as HER2+ on the primary tumor. Nine of
these 11 patients were now among those patients not
responding to different kinds of therapy. Recent work from the
group of Wicha [34] suggests a strong link between HER2-
like-tumors and stem cells. They reported that modulation of
signaling molecules such as phosphatase and tensin homo-
Figure 2
Correlation of circulating tumor cells (CTCs), epidermal/mesenchymal  transition (EMT) markers, and/or ALDH1 Correlation of circulating tumor cells (CTCs), epidermal/mesenchymal 
transition (EMT) markers, and/or ALDH1. (a) The identification of EMT 
markers was considered positive if at least one marker was detected in 
the sample. (b) Detailed analysis for the correlation of CTC and ALDH1 
as well as the EMT markers.
Figure 3
Correlation of epidermal/mesenchymal transition (EMT) markers or  ALDH1 or both with response to therapy Correlation of epidermal/mesenchymal transition (EMT) markers or 
ALDH1 or both with response to therapy. (a) The identification of EMT 
markers was considered positive if at least one marker was detected in 
the sample. Patients are stratified into responders and nonresponders. 
(b) Detailed analysis for the correlation of ALDH1 as well as the EMT 
markers and response to therapy.Breast Cancer Research    Vol 11 No 4    Aktas et al.
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logue on chromosome 10 (PTEN) or HER2 can increase the
size of the stem cell population.
The metastatic potential of a tumor depends on multiple fac-
tors that determine tumor growth, survival, angiogenesis, and
invasion. In this context, EMT is considered to be one of the
factors to be involved in the metastatic process. These cells
have reduced apoptosis and are drug resistant. A recent
report suggests that a direct link might exist between the EMT
and the acquisition of stem cell properties [35]. Furthermore,
cells undergoing EMT could be the precursors to metastatic
cancer cells, perhaps even metastasis-forming CTCs. In our
study, ALDH1 was frequently coexpressed with one of the
EMT markers analyzed, resulting in cancer progression and
therapy failure. Although the patient number at the moment is
too small to draw any significant conclusions, during follow-up
of the patients, ALDH1 and EMT markers were sometimes
detected before the appearance of CTCs in the circulation.
Further studies and longer follow-up times are needed to eval-
uate whether a systemic marker pattern can indicate early a
reappearance of CTCs, and thus a progressive process of the
disease.
EMT is known to occur in embryonic development, in which
epithelial cells must escape structural constraints imposed by
tissue architecture. They achieve this by adopting a phenotype
more amenable to cell movement. The progression of carcino-
mas to invasive and metastatic disease shows high similarities
to this process. Previous epithelial tumor cells that may con-
vert into a mesenchymal phenotype could, therefore, escape
the primary tumor tissue and develop resistance against con-
ventional therapy regimens (for example, antihormone treat-
ment) because they lost the relevant therapeutic targets
during that transformation [36]. Conversely, it might also be
possible that the expression of potential therapeutic targets,
like the HER2-receptor, is induced in such cells, even if the pri-
mary tumor was found to be negative for these targets [37].
Recently published data, analyzing 16 patients with early
breast cancer and 16 patients with metastatic breast cancer
with immunocytochemical double staining, demonstrated that
CTCs express receptors and activating signaling kinases of
the EGFR/HER2/PI3K/Akt pathway, which could be used as
targets for their effective elimination [38].
Conclusions
EMT characteristics are detectable in CTCs analyzed in meta-
static breast cancer samples, suggesting a negative prognos-
tic impact of such cells because of the EMT switch that leads
to decreased apoptosis and the development of chemoresist-
ance. Furthermore, an overexpression of ALDH1, detected in
a substantial number of our samples, indicates that CTCs
might often display tumor stem cell characteristics, highlight-
ing their role in metastasis formation. The detection and char-
a c t e r i z a t i o n  o f  C T C s  t h a t  s h o w  a n  E M T  o r  s t e m  c e l l - l i k e
metabolism could be a powerful diagnostic tool for patient
stratification, the early determination of therapy failure, or the
potential risk of resistance to a given therapeutic intervention.
Conversely, new therapeutic strategies consisting of molecu-
lar targeting of signal-transduction pathways activated in can-
cer stem cells have to be developed to eliminate minimal
residual disease.
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